Market Place
Sourcing Support
Afamelanotide in fair-skinned Parkinson’s patients
17 Jun 2024 //
GLOBENEWSWIRE
Photomedicine CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors
28 Mar 2024 //
GLOBENEWSWIRE
Malibu shines a light on CLINUVELs pioneering work in photomedicine
04 Mar 2024 //
GLOBENEWSWIRE
CLINUVEL Launches CYACÊLLE, Next Generation Solar Care
28 Feb 2023 //
GLOBENEWSWIRE
Global SCENESSE demand drives increased CLINUVEL revenues, earnings
23 Feb 2023 //
GLOBENEWSWIRE
CLINUVEL Drug Reduces Critical UV Skin Damage in Fair-Skinned Individuals
01 Feb 2023 //
GLOBENEWSWIRE
Clinuvel reports data from xeroderma pigmentosum therapy trial
16 Jan 2023 //
CLINICAL TRIALS ARENA
CLINUVEL Trial Results Show Drug Reduces DNA Damage
15 Jan 2023 //
GLOBENEWSWIRE
CLINUVEL progresses vitiligo treatment program
09 May 2022 //
GLOBENEWSWIRE
Letter to shareholders from CLINUVEL`s CEO
29 Apr 2022 //
GLOBENEWSWIRE
CLINUVEL Expands Pharmaceutical Portfolio
07 Nov 2021 //
GLOBENEWSWIRE
First stroke patient treated with afamelanotide
07 Jun 2021 //
PRESS RELEASE
CLINUVEL progresses innovative DNA Repair Program
10 Sep 2020 //
GLOBENEWSWIRE
CLINUVEL Opens VALLAURIX R&D Centre In Singapore
30 Aug 2020 //
GLOBENEWSWIRE
Clinuvel launches second afamelanotide formulation
14 Jul 2020 //
BIOSPECTRUMASIA
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.